FDA Reclassifies Hyperhidrosis Skin Patch to Class II, Improving Patient Access

The Food and Drug Administration (FDA) has reclassified a skin patch for treating hyperhidrosis, or excessive sweating, into Class II with special controls. This regulatory adjustment aims to ensure the device's safety and effectiveness while simultaneously reducing regulatory hurdles. The move is expected to enhance patient access to this innovative medical device.